Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline flush. Clear all
Completed Phase 4 Interventional Results available

BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury

NCT05025449
View directory record Official record
Conditions
Abdominal Trauma
Interventions
Focused Assessment with Sonography for Trauma (FAST), Bubble-Enhanced FAST (BEFAST)
Diagnostic Test · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

NCT02036281
View directory record Official record
Conditions
Terminally Ill, Histologically-confirmed Advanced Cancer, Pain, Intractable
Interventions
Substance P-Saporin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 24, 2026, 4:43 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

NCT06414356
View directory record Official record
Conditions
Neuropathic Pain, PTSD
Interventions
Ketamine, Magnesium sulfate, Ketamine + Magnesium sulfate
Drug
Lead sponsor
Margaux M. Salas, PhD
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 24, 2026, 4:43 PM EDT
Terminated Phase 4 Interventional Results available

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

NCT00934661
View directory record Official record
Conditions
Hip Arthroplasty
Interventions
Extended Release Epidural Morphine (EREM), Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 24, 2026, 4:43 PM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 24, 2026, 4:43 PM EDT
Terminated Phase 4 Interventional Results available

Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

NCT02923830
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other · Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Cincinnati, Ohio • Hamilton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 24, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

NCT06777433
View directory record Official record
Conditions
Brain Metastases From Solid Tumors
Interventions
RAD101 (18F-FPIA)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Hoffman Estates, Illinois • Goshen, Indiana • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

NCT00920855
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bendamustine, bortezomib
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Encinitas, California • Roseville, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 24, 2026, 4:43 PM EDT
Not yet recruiting No phase listed Observational

Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma

NCT07825597
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Indocyanine green, Near-infrared fluorescence imaging
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

NCT01572701
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

NCT03497377
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
18F-DCFPyL Injection, 18F-NaF
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 24, 2026, 4:43 PM EDT
Recruiting Phase 1 Interventional

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ureteral Patency in the Post-indigo Carmine Era

NCT02677623
View directory record Official record
Conditions
Ureteral Patency
Interventions
Pyridium, Sodium Fluorescein, Mannitol, Normal Saline
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 24, 2026, 4:43 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of Endobronchial Ultrasound Needle Cleaning Techniques and Their Impact on Specimen Contamination

NCT07461662
View directory record Official record
Conditions
Lung Cancer (Locally Advanced or Metastatic)
Interventions
Purge cleaning
Diagnostic Test
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions

NCT02413125
View directory record Official record
Conditions
Sinusitis
Interventions
ChitoRhino irrigation solution, Normal saline
Device · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 24, 2026, 4:43 PM EDT
Recruiting No phase listed Observational

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

NCT07335315
View directory record Official record
Conditions
Pituitary Adenoma, Cushing Disease
Interventions
Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Edgewater, Florida • Orlando, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 24, 2026, 4:43 PM EDT
Completed Not applicable Interventional

70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014

NCT02441075
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, GVHD
Interventions
70% Ethanol
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Months to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 24, 2026, 4:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
View directory record Official record
Conditions
Glomerular Filtration Rate
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

NCT05501366
View directory record Official record
Conditions
Ketosis
Interventions
Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis
Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 30 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 4:43 PM EDT